Another ongoing clinical trial (NCT04499365) plans to enroll 500 subjects for 68Ga-DOTA/NOTA-FAPI-04 PET to provide robust clinical evidence regarding the use of FAP-targeted imaging for the diagnosis of primary and metastatic lesions in various types of cancer [327]. The gene discussed is FAP; the disease is cancer.